Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer

Journal of the Medical Association of Thailand

Volumn 90, Issue 11, 2007, Pages 2506-2512

  Charoentum, Chaiyut ^a,b   Thongprasert, Sumitra ^a   Chewasakulyong, Busayamas ^a   Euathrongchit, Juntima ^a   Sorraritchingchai, Sirikul ^a   Munprakan, Sutthirak ^a  

^a CHIANG MAI UNIVERSITY   (Thailand)

^b Maharaj Nakorn Chiang Mai Hospital   (Thailand)

Author keywords

Cisplatin; Docetaxel; Irinotecan; Non small cell lung cancer; Phase II study

Indexed keywords

CISPLATIN; DOCETAXEL; IRINOTECAN;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; RASH; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; TAXOIDS; TREATMENT OUTCOME;

EID: 37149053450     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Nonsmall Cell Lung Cancer Collaborative Group. BMJ 1995; 311: 899-909.
2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-8.
3. Sandler A, van Oosterom AT. Irinotecan in cancers of the lung and cervix. Anticancer Drugs 1999; 10 Suppl 1: S13-S17.
4. Masuda N, Fukuoka M, Negoro S. A randomized trial comparing cisplatin and irinotecan vs cisplatin and vindesine vs CPT-11 alone in advanced nonsmall cell lung cancer (NSCLC): a multicenter phase III study (abstract 1774). Proc Amer Soc Clin Oncol 1999; 18: 459a.
5. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18: 2354-62.
6. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-103.
7. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727-33.
8. American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1996; 14: 1957-60.
9. World Health Organization. WHO handbook for reporting results of cancer treatment. WHO Offset Publication No. 48. Geneva, Switzerland: WHO; 1979.
10. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
11. Kosmidis P, Mylonakis N, Nicolaides C, Kalophonos C, Samantas E, Boukovinas J, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2002; 20: 3578-85.
12. Alberola V, Camps C, Provencio M, Isla D, Rosell R, Vadell C, et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 2003; 21: 3207-13.
13. Norton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 1977; 61: 1307-17.
14. de Jonge MJ, Sparreboom A, Planting AS, van der Burg ME, Boer-Dennert MM, ter Steeg J, et al. Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors. J Clin Oncol 2000; 18: 187-94.
15. Masuda N, Fukuoka M, Fujita A, Kurita Y, Tsuchiya S, Nagao K, et al. A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group. Br J Cancer 1998; 78: 251-6.
16. DeVore RF, Johnson DH, Crawford J, Garst J, Dimery IW, Eckardt J, et al. Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 1999; 17: 2710-20.
17. Jagasia MH, Langer CJ, Johnson DH, Yunus F, Rodgers JS, Schlabach LL, et al. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study. Clin Cancer Res 2001; 7: 68-73.
18. Cardenal F, Domine M, Massuti B, Carrato A, Felip E, Garrido P, et al. Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study. Lung Cancer 2003; 39: 201-7.
19. Edelman MJ, Clark JI, Chansky K, Albain K, Bhoopalam N, Weiss GR, et al. Randomized phase II trial of sequential chemotherapy in advanced nonsmall cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin Cancer Res 2004; 10: 5022-6.
20. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003; 21: 2237-46.
21. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-58.
22. Shepherd FA, Rodrigues PJ, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-32.